Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
European Journal of Endocrinology|January 30, 2026
Somapacitan in Children Born Small for Gestational Age: 4-year Results from Phase 2Anders Juul, Michael Højby, Masanobu Kawai, et al.
Clinical Endocrinology|June 29, 2017
Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trialTadej Battelino, Michael Højby Rasmussen, Jean De Schepper, et al.
Pediatric Research|May 6, 2011
11β-Hydroxysteroid dehydrogenase type 1 activity in short small-for-GA children and in response to GH therapyNehama Zuckerman-Levin, Larisa Tsivlin, Carlos Knopf, et al.
The Journal of Clinical Endocrinology and Metabolism|November 2, 2006
Parturition itself is the basis for fetal adrenal involutionShlomit Ben-David, Nehama Zuckerman-Levin, Monica Epelman, et al.
European Journal of Endocrinology|January 18, 2023
Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 studyAnders Juul, Philippe Backeljauw, Michael Højby, et al.
European Journal of Pediatrics|July 18, 2018
A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)Mark D Wheeler, Margarita Barrientos-Perez, Fu-Sung Lo, et al.
Eating and Weight Disorders : EWD|October 18, 2018
Dietary patterns of patients with binge eating disorders with and without night eatingYael Latzer, Adi Elron Yutal, Miri Givon, et al.
Pediatric Diabetes|May 21, 2021
Endothelin-1 levels are decreased in pediatric Type 1 diabetes and negatively correlate with the carotid intima media thicknessMichal Cohen, Hiba Yaseen, Mogher Khamaisi, et al.
The Journal of Pediatrics|June 26, 2012
Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressureIlan Youngster, Rony Rachmiel, Orit Pinhas-Hamiel, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2024
Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 StudyAnders Juul, Philippe Backeljauw, Michael Højby, et al.
Pageof 4